Physician profile
Mark Hallen Flasar
NPI 1326079278
$143,276.85
in general payments reported to CMS, 2019-2025
44 companies · $19K in 2025
The $19K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $3,692 · 2021: $3,531 · 2022: $29K · 2023: $27K · 2024: $38K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Travel and Lodging: $11K · Consulting Fee: $11K · Food and Beverage: $6,887 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,487.50 |
| Travel and Lodging | $10,998.17 |
| Consulting Fee | $10,782.50 |
| Food and Beverage | $6,886.87 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $124,751.38 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $8,947.24 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $5,139.45 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $652.96 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $419.48 | 2019-2024 | Trulance, Xifaxan |
| Celgene Corporation | $368.94 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $367.06 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $338.34 | 2019-2025 | Ocaliva |
| Qol Medical, LLC | $307.98 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $165.55 | 2022-2024 | |
| Gilead Sciences, INC. | $149.23 | 2019-2025 | |
| Amgen INC. | $139.27 | 2020-2023 | Amjevita, Avsola |
| Ipsen Biopharmaceuticals, INC | $132.12 | 2024-2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $124.90 | 2022-2024 | Rebyota, Cimzia |
| Braintree Laboratories, INC. | $119.66 | 2019-2023 | Sutab |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Flasar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.